ArticleInteractive journal of medical research2026
Value of Blood Count-Derived Inflammatory Markers for Evaluating Psoriasis Severity: Pilot Cross-Sectional Observational Study.
Article in Interactive journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Objective indicators are urgently needed to evaluate and monitor disease progression in patients with psoriasis. Objective: This study aimed to verify the correlations between blood count-derived inflammatory markers and the Psoriasis Area and Severity Index (PASI) among patients with psoriasis and explore the value of applying the PASI in combination with proinflammatory factors. Methods: This was a cross-sectional observational study that enrolled 719 patients from 2 tertiary hospitals. Receiver operating characteristic curve analysis and binary logistic regression models were applied to assess the evaluative power of blood count-derived inflammatory markers and their consistency with the PASI for stratifying psoriasis severity. The association with the PASI and the combination with proinflammatory factors of the blood count-derived inflammatory markers in 60 patients were analyzed. The exploratory association between blood count-derived markers and proinflammatory factors was analyzed using product terms. To ensure robustness, multivariable combined models were evaluated using receiver operating characteristic curves and decision curve analysis. Model performance was further validated via calibration plots and a predictive nomogram, with the decision curve analysis net benefit axis increased to 1.0 for comprehensive visualization. Results: The area under the curve showed that the systemic immune-inflammation index (SII), systemic inflammation response index (SIRI), and aggregate index of systemic inflammation (AISI) were effective in reflecting psoriasis severity and showed advantages in patients with psoriasis complicated by arthritis and cardiovascular metabolic diseases. The comprehensive test showed quite appropriate consistency of the SIRI and PASI in distinguishing severity. The SII, SIRI, and AISI were significantly correlated with interleukin (IL)-6 in lesions (all P<.05), and the combinations of these indices with IL-6, IL-1, and IL-17 were also significantly correlated with the PASI (all P<.05). Conclusions: Blood count-derived inflammatory markers could better reflect the inflammation of patients with psoriasis. The SII, SIRI, and AISI have important clinical significance in evaluating disease severity. The combination with proinflammatory factors showed an advantage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.